M
Myelo Therapeutics
Innovative treatments in areas of high unmet medical needs
About Myelo Therapeutics
Myelo Therapeutics GmbH is a Berlin-based clinical-stage pharmaceutical company established in 2013, concentrating on the development of treatments for conditions with significant unmet medical needs. The company was acquired by Eckert & Ziegler Strahlen- und Medizintechnik AG in December 2022 and now operates as a fully owned subsidiary.
The firm's primary focus is on its lead compound, Myelo001, an orally administered small molecule designed to address myelosuppression—a reduction in blood cell production—which is a common and severe side effect of chemotherapy and radiotherapy. Myelosuppression can lead to treatment interruptions and heightened risk of infection, potentially compromising the effectiveness of cancer therapies. Myelo001 works by protecting immature granulocytic cells and promoting the maturation of neutrophils, which are crucial white blood cells for fighting infection. The product is being investigated for treating chemotherapy-induced myelosuppression (CIM), radiation-induced myelosuppression (RIM), and as a medical countermeasure for Acute Radiation Syndrome (ARS) resulting from nuclear incidents.
Myelo Therapeutics operates through a combination of in-house research and strategic collaborations with contract research organizations and universities. The development of Myelo001 has received significant support, including contracts from the U.S. National Institute of Allergy and Infectious Diseases (NIAID), valued at up to $6.5 million, and grants from the European Defence Fund. The company has successfully navigated key regulatory milestones, including a Pre-Investigational New Drug (IND) meeting with the U.S. FDA and has received Orphan Drug Designation from both the FDA and the European Medicines Agency (EMA) for the treatment of ARS.
Clinical trials have been a central part of the company's progression. A Phase IIa study was initiated to evaluate the efficacy and safety of Myelo001 in reducing chemotherapy-induced neutropenia in breast cancer patients. The business model is centered on advancing Myelo001 through the clinical and regulatory pipeline toward market authorization, targeting a global market for supportive cancer care estimated at USD 8 billion. Key investors prior to its acquisition included Eckert Life Science Accelerator, IBB Ventures, and JSC Valenta Pharmaceuticals.
Source: Dealroom company dataNews
Open roles
Myelo Therapeutics in the Berlin ecosystem
The Myelo Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
European Commission
Series A1 investor entered at this stage
IBB Ventures
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Myelo Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Myelo Therapeutics on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.


